Combination of Cliengitide and Oncolytic HSV: a toxicology study for brain tumors

描述（由申请人提供）：本提案的最终目标是培养Dr. Kaur成为一名独立的翻译研究员。他于2005年2月加入The Ohio State University，担任终身助理教授。她在Van Meir博士的指导下完成了博士后培训，在那里她确立了自己作为一名可靠且非常富有成效的研究人员的地位。在她的博士后研究期间，她意识到她的激情在于翻译事业，在那里她可以运用她的科学训练，使治疗方案更接近患者。这项指导资助申请对她学习必要的技能至关重要，使她成为临床前转化研究的独立研究者。她的长期目标是发展成为一名富有成效的独立转化研究人员，可以指导临床前毒理学和药代动力学研究，将研究药物迅速从实验室工作台转移到临床。拟议的五年计划包括职业培训和一个研究项目，以发展实现这一目标的技能。该计划包括正式的课程作业、研讨会、讲习班和以翻译研究为重点的会议。这个五年计划包括与候选人的主要和次要导师的定期互动。被选中指导Kaur博士发展的导师都是有成就的医生，他们有参与临床试验和指导年轻研究人员的记录。候选人还安排参加与负责任的研究行为有关的讲习班。此外，候选人将参加与拨款写作和实验室管理有关的研讨会，以促进成功的R01申请的发展，这对建立她作为独立的转化研究人员至关重要。俄亥俄州立大学NCI指定的综合癌症中心（OSUCCC）为这项培训提供了理想的场所。OSUCCC致力于将实验室结果转化为患者，并认识到培训基础研究科学家以推进转化研究的必要性。该机构致力于候选人的发展，并完全支持她将75%的时间用于实现这一目标的决定。这项申请旨在研究由她的主要导师产生的一种新型溶瘤病毒与一种抗血管生成药物联合治疗脑肿瘤的临床前疗效毒理学。该提案的主体是基于一个OV平台，该平台在胶质瘤模型中显示出显著且无与伦比的疗效，并且可以通过使用已知的抗血管生成药物西伦吉肽调节肿瘤微环境来增强这种疗效。

DESCRIPTION (provided by applicant): The ultimate goal of this proposal is to train Dr. Kaur to be an independent translational researcher. Dr. Kaur joined The Ohio State University as a tenure track Assistant Professor in February 2005. She completed her postdoctoral training with Dr. Van Meir, where she established herself as a reliable and very productive researcher. During her postdoctoral research she realized that her passion lies in a translational career where she can apply her scientific training to bring treatment options closer to the patients. This mentored grant application is essential for her to learn the required skills essential to launch her as an independent investigator in preclinical translational research. Her long term goal is to develop into a productive independent translational researcher who can guide preclinical toxicological and pharmacokinetic studies of investigational agents to move them rapidly from the laboratory bench to the clinics. The five year plan proposed consists of career training and a research project to develop skills towards achieving this goal. The plan includes formal course work, seminars, work shops, and meetings focusing on translational research. This five year plan includes regular interactions with the candidate's primary and secondary mentors. The Mentors selected to guide the development of Dr. Kaur are accomplished physicians, with a track record of involvement in clinical trials and mentoring young investigators. The candidate has also arranged to attend workshops pertaining to responsible conduct of research. Additionally the candidate will enroll in workshops pertaining to grant writing and laboratory management, to facilitate the development of a successful R01 application essential to establish her as an independent translational researcher. The Ohio State University's NCI designated Comprehensive Cancer Center (OSUCCC) provides the ideal location for this training. The OSUCCC is dedicated towards the cause of translating laboratory findings to the patient, and recognizes the need to train basic research scientists to advance translational research. The institution is committed towards the development of the candidate and fully supports her decision to commit 75% of her time towards this goal. This application proposes to investigate the preclinical efficacy toxicology of a novel oncolytic virus generated by her primary mentor in combination with an anti-angiogenic agent for treatment of brain tumors. The body of this proposal is based on a platform for an OV that shows significant and unparalleled efficacy in glioma models, and that this efficacy can be enhanced by modulating tumor microenvironment with Cilengitide, a known antiangiogenic agent.